Profile data is unavailable for this security.
About the company
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. It is focused on translating insights from genetic epilepsies into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, is an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. Its product candidates include ulixacaltamide, PRAX-562, PRAX-628 and elsunersen.
- Revenue in USD (TTM)1.61m
- Net income in USD-151.02m
- Incorporated2015
- Employees82.00
- LocationPraxis Precision Medicines Inc99 High Street, 30th FloorBOSTON 02110United StatesUSA
- Phone+1 (617) 300-8460
- Fax+1 (302) 655-5049
- Websitehttps://praxismedicines.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CareDx Inc | 312.78m | -143.56m | 1.21bn | 635.00 | -- | 4.39 | -- | 3.87 | -2.70 | -2.70 | 5.95 | 5.15 | 0.6395 | 5.75 | 5.29 | 492,559.10 | -29.35 | -17.54 | -34.84 | -20.85 | 65.77 | 65.50 | -45.90 | -27.78 | 3.87 | -- | 0.00 | -- | -12.89 | 29.63 | -148.37 | -- | 5.01 | -- |
| Ardelyx Inc | 251.85m | -72.58m | 1.21bn | 267.00 | -- | 7.66 | -- | 4.82 | -0.3113 | -0.3113 | 1.08 | 0.6682 | 0.7664 | 3.76 | 5.22 | 943,254.70 | -22.09 | -46.14 | -26.72 | -57.32 | 85.16 | 88.15 | -28.82 | -240.87 | 3.87 | -5.94 | 0.3888 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| Enliven Therapeutics Inc | 0.00 | -85.21m | 1.24bn | 57.00 | -- | 4.16 | -- | -- | -1.91 | -1.91 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -29.41 | -42.26 | -30.97 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Maravai Lifesciences Holdings Inc | 276.92m | -224.66m | 1.25bn | 580.00 | -- | 3.63 | -- | 4.52 | -1.65 | -1.65 | 2.04 | 1.37 | 0.1562 | 2.98 | 7.43 | 426,030.80 | -18.23 | 12.67 | -23.39 | 15.46 | 46.36 | 74.79 | -116.68 | 37.32 | 9.94 | -1.47 | 0.4746 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
| Aurinia Pharmaceuticals Inc | 220.36m | -22.55m | 1.26bn | 300.00 | -- | 3.23 | -- | 5.70 | -0.1582 | -0.1582 | 1.53 | 2.71 | 0.3991 | 0.7854 | 5.92 | 734,536.70 | -4.08 | -25.97 | -4.74 | -28.24 | 87.25 | -- | -10.23 | -137.64 | 5.11 | -- | 0.1725 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Novavax Inc | 885.19m | -284.86m | 1.29bn | 1.54k | -- | -- | -- | 1.45 | -2.26 | -2.26 | 6.00 | -3.29 | 0.5254 | 8.19 | 8.10 | 573,683.10 | -16.91 | -46.06 | -79.12 | -269.57 | 63.79 | -- | -32.18 | -75.94 | 0.9272 | -17.46 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| ARS Pharmaceuticals Inc | 2.57m | -49.10m | 1.30bn | 146.00 | -- | 6.47 | -- | 505.09 | -0.5076 | -0.5076 | 0.0266 | 2.07 | 0.011 | -- | -- | 107,000.00 | -21.07 | -20.37 | -22.40 | -21.32 | 76.17 | -- | -1,912.15 | -17,491.75 | 12.52 | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Arcus Biosciences Inc | 263.00m | -270.00m | 1.31bn | 577.00 | -- | 2.31 | -- | 4.97 | -3.15 | -3.15 | 3.06 | 6.17 | 0.2153 | -- | 6.83 | 455,805.90 | -22.10 | -15.85 | -26.63 | -18.25 | -- | -- | -102.66 | -103.46 | -- | -- | 0.0768 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
| Syndax Pharmaceuticals Inc | 16.00m | -297.06m | 1.33bn | 112.00 | -- | 3.64 | -- | 83.22 | -3.63 | -3.63 | 0.1949 | 4.28 | 0.0388 | -- | 3.60 | 142,857.10 | -72.01 | -27.90 | -81.78 | -30.15 | -- | -- | -1,856.64 | -324.34 | -- | -- | 0.00003 | -- | -- | -- | -40.19 | -- | -- | -- |
| Day One Biopharmaceuticals Inc | 101.95m | -84.29m | 1.35bn | 174.00 | -- | 2.42 | -- | 13.20 | -1.02 | -1.02 | 1.14 | 5.51 | 0.2009 | -- | -- | 657,761.30 | -16.61 | -- | -17.73 | -- | 97.75 | -- | -82.68 | -- | 14.55 | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
| MiMedx Group Inc | 342.81m | 90.79m | 1.35bn | 895.00 | 18.59 | 7.49 | 13.61 | 3.95 | 0.4961 | 0.4601 | 2.00 | 1.23 | 1.58 | 2.63 | 6.65 | 383,022.30 | 44.93 | -4.14 | 56.00 | -5.90 | 83.37 | 83.61 | 28.37 | -2.70 | 3.53 | 22.35 | 0.0951 | -- | 20.03 | -2.19 | 310.29 | -- | -26.47 | -- |
| Praxis Precision Medicines Inc | 1.61m | -151.02m | 1.36bn | 82.00 | -- | 3.40 | -- | 848.40 | -10.29 | -10.29 | 0.1058 | 21.52 | 0.0061 | -- | -- | 19,573.17 | -57.75 | -74.04 | -63.81 | -85.12 | -- | -- | -9,409.22 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| Spyre Therapeutics Inc | 0.00 | -214.90m | 1.39bn | 60.00 | -- | 8.09 | -- | -- | -7.44 | -7.44 | 0.00 | 6.37 | 0.00 | -- | -- | 0.00 | -68.40 | -101.87 | -81.72 | -118.83 | -- | -- | -- | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
| Bicycle Therapeutics PLC (ADR) | 36.90m | -166.28m | 1.40bn | 284.00 | -- | 1.68 | -- | 37.91 | -3.28 | -3.28 | 0.7163 | 12.04 | 0.0451 | -- | 0.9806 | 129,922.50 | -20.33 | -29.45 | -22.03 | -32.98 | -- | -- | -450.64 | -571.36 | -- | -- | 0.0002 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| Intellia Therapeutics Inc | 43.09m | -522.28m | 1.40bn | 526.00 | -- | 1.46 | -- | 32.53 | -5.45 | -5.45 | 0.4509 | 9.46 | 0.0357 | -- | 5.62 | 81,912.55 | -43.22 | -31.34 | -47.07 | -34.53 | -- | -- | -1,212.19 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
Data as of Nov 21 2024. Currency figures normalised to Praxis Precision Medicines Inc's reporting currency: US Dollar USD
55.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.19m | 6.71% |
| Perceptive Advisors LLCas of 30 Sep 2024 | 1.16m | 6.56% |
| Point72 Asset Management LPas of 30 Sep 2024 | 1.10m | 6.19% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 1.09m | 6.12% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2024 | 997.09k | 5.62% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 992.38k | 5.59% |
| Cormorant Asset Management LPas of 30 Sep 2024 | 870.00k | 4.90% |
| Adage Capital Management LPas of 30 Sep 2024 | 854.08k | 4.81% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 789.62k | 4.45% |
| RA Capital Management LPas of 30 Sep 2024 | 761.96k | 4.29% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
